论文部分内容阅读
[目的]观察复方参芪软胶囊对儿童功能性消化不良患者胃肠动力的影响,并探讨其临床疗效。[方法]选取2015年4月~2016年8月我院收治的功能性消化不良患儿144例,患儿使用数字表法随机分为对照组和观察组,每组72例。对照组口服莫沙必利5mg/次,3次/d。观察组在对照组基础上加用复方参芪软胶囊2粒/次,2次/d,14d为一疗程。超声显像检测胃窦排空率,比较2组临床疗效和不良反应发生率。[结果]观察组30、60和90min的胃窦排空率分别为(15.37±3.86)%、(42.31±7.93)%和(31.64±6.13)%,均分高于对照组的(11.24±2.95)%、(27.46±4.78)%和(20.15±4.22)%(P<0.05或P<0.01)。上腹痛、腹胀、食欲不振、嗳气、恶心、呕吐症状评分2组间差异无统计学意义(P>0.05),治疗后上述症状评分均显著减低(P<0.05或P<0.01),但观察组对上述症状评分的减低幅度显著高于对照组(P<0.05)。观察组临床治疗有效率为91.7%(66/72),显著高于对照组的76.4%(55/72)(P<0.05)。观察组不良反应发生率为5.6%(4/72),对照组不良反应发生率为6.9%(5/72),2组间差异无统计学意义(P>0.05)。[结论]复方参芪软胶囊可以显著增加功能性消化不良患儿的胃肠功能,临床疗效显著,使用安全。
[Objective] To observe the effect of compound Shenqi Soft Capsule on gastrointestinal motility in children with functional dyspepsia and to investigate its clinical efficacy. [Methods] A total of 144 children with functional dyspepsia admitted in our hospital from April 2015 to August 2016 were randomly divided into control group and observation group with digital watch method, with 72 cases in each group. Control group oral mosapride 5mg / time, 3 times / d. Observation group in the control group based on the use of compound Shenqi soft capsule 2 / times, 2 times / d, 14d for a course of treatment. Ultrasound imaging detection of gastric emptying rate, the clinical efficacy and adverse reactions in two groups were compared. [Results] The gastric emptying rates in the observation group at 30, 60 and 90 min were (15.37 ± 3.86)%, (42.31 ± 7.93)% and (31.64 ± 6.13)%, respectively, higher than those in the control group (11.24 ± 2.95 ), (27.46 ± 4.78)% and (20.15 ± 4.22)%, respectively (P <0.05 or P <0.01). There was no significant difference between the two groups in the symptoms of abdominal pain, abdominal distension, loss of appetite, belching, nausea and vomiting (P> 0.05), and the scores of these symptoms were significantly decreased after treatment (P <0.05 or P <0.01) The reduction of the above symptom score was significantly higher than that of the control group (P <0.05). The effective rate of clinical treatment in observation group was 91.7% (66/72), which was significantly higher than that in control group (76.4%, 55/72) (P <0.05). The incidence of adverse reactions in the observation group was 5.6% (4/72), and the incidence of adverse reactions in the control group was 6.9% (5/72). There was no significant difference between the two groups (P> 0.05). [Conclusion] Compound Shenqi soft capsule can significantly increase the gastrointestinal function in children with functional dyspepsia. The clinical effect is significant and safe to use.